40724-47-8

Basic information

• Product Name: 4-BROMOMETHYL-BENZENESULFONAMIDE
• Synonyms: 4-(broMoMethyl)benzene-1-sulfonaMide;p-Bromomethylbenzenesulfonamide;4-BROMOMETHYL-BENZENESULFONAMIDE;4-sulfonamide benzyl bromide
• CAS NO: 40724-47-8
• Molecular Formula: C₇H₈BrNO₂S
• Molecular Weight: 250.11292
• Mol File: 40724-47-8.mol
• Article Data: 18

Chemical Properties

• Melting Point: 191-192℃
• Boiling Point: 386.4 °C at 760 mmHg
• Flash Point: 187.5 °C
• Appearance: /
• Density: 1.691
• Vapor Pressure: 3.56E-06mmHg at 25°C
• Refractive Index: 1.614
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 9.99±0.10(Predicted)
• CAS DataBase Reference: 4-BROMOMETHYL-BENZENESULFONAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-BROMOMETHYL-BENZENESULFONAMIDE(40724-47-8)
• EPA Substance Registry System: 4-BROMOMETHYL-BENZENESULFONAMIDE(40724-47-8)

Safety Data

• Hazardous Substances Data: 40724-47-8(Hazardous Substances Data)

Usage

General Description

4-Bromomethyl-benzenesulfonamide is a chemical compound with the molecular formula C7H8BrNO2S. It is a white to off-white solid that is used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. 4-BROMOMETHYL-BENZENESULFONAMIDE is known for its potential applications as an antimicrobial and antibacterial agent. It is also used as a building block in the production of various organic compounds. 4-Bromomethyl-benzenesulfonamide is considered to be a moderately hazardous substance, and proper handling and storage precautions should be taken when working with it.

InChI:InChI=1/C7H8BrNO2S/c8-5-6-1-3-7(4-2-6)12(9,10)11/h1-4H,5H2,(H2,9,10,11)

Upstream product

• 66176-39-4 4-(bromomethyl)benzene-1-sulfonyl chloride 
• 67472-44-0 4-(hydroxymethyl)benzenesulfonamide 
• 3240-35-5 4-formyl-benzenesulfonamide 
• 3119-02-6 4-cyanobenzenesulfonamide 
• 63-74-1 sulfanilamide 
• 98-59-9 p-toluenesulfonyl chloride 
• 70-55-3 toluene-4-sulfonamide 

Downstream Products

• 109841-80-7 formylamino-(4-sulfamoyl-benzyl)-malonic acid diethyl ester 
• 128577-50-4 N-Benzoyl-4-bromomethyl-benzenesulfonamide 
• 913078-94-1 4-{[2-{isobutyl[(5-methyl-2-furyl)sulfonyl]amino}-5-(trifluoromethyl)phenoxy]methyl}benzenesulfonamide 
• 128598-89-0 2-Ethyl-hexanoic acid [1-(4-benzoylsulfamoyl-benzyl)-1H-indol-6-yl]-amide 
• 54473-03-9 4-sulfamoyl-phenylalanine 

Relevant articles and documents

INSULIN CONJUGATES

The present invention relates to a conjugate comprising a sulfonamide of formula (I) and an active pharmaceutical ingredient such as an insulin analog comprising at least one mutation relative to the parent insulin, wherein the insulin analog comprises a mutation at position B16 which is substituted with a hydrophobic amino acid and/or a mutation at position B25 which is substituted with a hydrophobic amino acid. The present invention further relates to a sulfonamide of formula (A). Moreover, the present invention relates to an insulin analog comprising at least one mutation relative to the parent insulin.

NLRP3 INHIBITORS

The present application relates to compounds with NLRP3inhibitory activity and to associated salts, solvates, prodrugs and pharmaceutical compositions. The present application further relates to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by NLRP3inhibition.

Design, Synthesis, and X-ray of Selenides as New Class of Agents for Prevention of Diabetic Cerebrovascular Pathology

A series of novel selenides bearing benzenesulfonamide moieties was synthesized and investigated for their inhibition on six human (h) carbonic anhydrase (CA, EC 4.2.1.1) isoforms such as the physiologically relevant hCA I, II, VA, VB, VII, and IX and the